Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease: The Problem of Under-Treatment

Author： McCabe C.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.3, Iss.3, 2003-01, pp. : 179-191

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 1, 2009-03 ,pp. : 1-26

Bentham Science Publishers

Access to resources Recommend Favorite

HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque

By  

Current Drug Targets, Vol. 3, Iss. 5, 2002-10 ,pp. : 379-385

Bentham Science Publishers

Access to resources Recommend Favorite

Safety Profiles for the HMG-CoA Reductase Inhibitors: Treatment and Trust

By Davidson M.H.  

Drugs, Vol. 61, Iss. 2, 2001-01 ,pp. : 197-206

Adis International

Access to resources Recommend Favorite

Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction: Are All HMG-CoA Reductase Inhibitors Alike?

By Maroo Bijesh P.   Lavie Carl J.   Milani Richard V.  

Drugs & Aging, Vol. 25, Iss. 8, 2008-01 ,pp. : 649-664

Adis International

Access to resources Recommend Favorite

The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function

By Tesfamariam Belay  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 2, 2006-01 ,pp. : 115-120

Adis International

Access to resources Recommend Favorite